| Title: |
AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT |
| Authors: |
Furst, D.; Keystone, E.; Kay, J.; Jaworski, J.; Wojciechowski, R.; Wiland, P.; Dudek, A.; Krogulec, M.; Jeka, S.; Zielinska, A.; Trefler, J.; Bartnicka-Masłowska, K.; Krajewska-Wlodarczyk, M.; Klimiuk, P.; Lee, S.J.; Kim, S.H.; Bae, Y.; Yang, G.; Yoo, J.; Kim, T. |
| Source: |
Annals of the Rheumatic Diseases ; volume 80, page 1123-1124 ; ISSN 0003-4967 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2021 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1136/annrheumdis-2021-eular.325 |
| Availability: |
https://doi.org/10.1136/annrheumdis-2021-eular.325; https://api.elsevier.com/content/article/PII:S0003496724519318?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0003496724519318?httpAccept=text/plain; https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-eular.325 |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license |
| Accession Number: |
edsbas.49574F1B |
| Database: |
BASE |